NHS Innovation Accelerator
Tony Doyle is a seasoned professional with extensive experience in the medical device and pharmaceutical industries. Since August 2010, Tony has served as the Managing Director of Qbtech, where the company has achieved significant growth and operational success across 11 countries, backed by three FDA clearances and over 400,000 patients supported through more than 30 ongoing studies. Tony also holds the position of NHS Innovation Accelerator Fellow, contributing to the advancement of selected innovations aligned with England's NHS priorities. Prior roles include Vice President of Hospital Sector Business Effectiveness and Head of Customer Marketing at Pfizer, where Tony was instrumental in establishing key strategies and teams to enhance customer engagement within the NHS. Tony's career began at Astra Pharmaceuticals in various sales roles, and academic credentials include a degree in Human Biology from The Manchester Metropolitan University.
This person is not in the org chart
This person is not in any teams
NHS Innovation Accelerator
1 followers
The NHS Innovation Accelerator (NIA) is an NHS England Initiative delivered in partnership with the country’s 15 Health Innovation Networks (HINs) and the Accelerated Access Collaborative. Hosted by UCLPartners, it supports delivery of the Five Year Forward View by accelerating uptake of high impact innovations for patient, population and NHS staff benefit, and providing real time practical insights on spread to inform national strategy. Fellows supported by the NIA all share a set of values and passion for scaling evidence-based innovation to benefit a wider population, with a commitment to share their learnings. Some impressive results have been achieved by Fellows since the NIA launched in July 2015: 2,980 additional NHS sites now using NIA innovations; £203 million in external funds secured; 193 awards won; 1,145 jobs created; and 57 innovations selling internationally. In addition, impact data is already available at adopter sites and this demonstrates earlier intervention, reductions in complications and emergency admissions, alongside cost savings.